Abstract
Monoamine oxidase (MAO) inhibitors continue to be used for treatment of a number of psychiatric and neurologic disorders. In recent years, inhibitors of MAO and other amine oxidases have received considerable attention because of their neuroprotective and neurorescue effects in such models as oxygen-glucose deprivation in vitro, thiamine deficiency, NMDA-instigated excitotoxicity, free radical-mediated oxidative stress, cerebral ischemia, and experimental models of Alzheimers and Parkinsons Diseases. This review focuses on the MAO inhibitors l-deprenyl, tranylcypromine and phenelzine and the possible mechanisms underlying their neuroprotective actions. In addition, there is a discussion of analogs of phenelzine and l-deprenyl as inhibitors of other amine oxidases, including semicarbazide-sensitive amine oxidase (SSAO), and their possible involvement in neuroprotection.
Keywords: neuroprotection, neurorescue, l-deprenyl, amine oxidase, semicarbazide-sensitive amine oxidase, phenelzine, phenylethylidenehydrazine
Current Neuropharmacology
Title: Amine Oxidase Inhibitors and Development of Neuroprotective Drugs
Volume: 2 Issue: 2
Author(s): Bernard N. Sowa, Kathryn G. Todd, A. M. I Tanay, Andrew Holt and Glen B. Baker
Affiliation:
Keywords: neuroprotection, neurorescue, l-deprenyl, amine oxidase, semicarbazide-sensitive amine oxidase, phenelzine, phenylethylidenehydrazine
Abstract: Monoamine oxidase (MAO) inhibitors continue to be used for treatment of a number of psychiatric and neurologic disorders. In recent years, inhibitors of MAO and other amine oxidases have received considerable attention because of their neuroprotective and neurorescue effects in such models as oxygen-glucose deprivation in vitro, thiamine deficiency, NMDA-instigated excitotoxicity, free radical-mediated oxidative stress, cerebral ischemia, and experimental models of Alzheimers and Parkinsons Diseases. This review focuses on the MAO inhibitors l-deprenyl, tranylcypromine and phenelzine and the possible mechanisms underlying their neuroprotective actions. In addition, there is a discussion of analogs of phenelzine and l-deprenyl as inhibitors of other amine oxidases, including semicarbazide-sensitive amine oxidase (SSAO), and their possible involvement in neuroprotection.
Export Options
About this article
Cite this article as:
Sowa N. Bernard, Todd G. Kathryn, I Tanay M. A., Holt Andrew and Baker B. Glen, Amine Oxidase Inhibitors and Development of Neuroprotective Drugs, Current Neuropharmacology 2004; 2 (2) . https://dx.doi.org/10.2174/1570159043476800
DOI https://dx.doi.org/10.2174/1570159043476800 |
Print ISSN 1570-159X |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6190 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Cyclopentenyl Cytosine (CPEC): An Overview of its in vitro and in vivo Activity
Current Cancer Drug Targets Ion Channel Architecture of the Renal Microcirculation
Current Hypertension Reviews Free Radicals Generated by Post-Prandial Oxidative Burst in the Early Alterations of Vascular Contractility
Clinical Immunology, Endocrine & Metabolic Drugs (Discontinued) Technology for the Production and Utilization of Food Protein-Derived Antihypertensive Peptides: A Review
Recent Patents on Biotechnology Monoclonal Antibodies in the Treatment of Leukemia
Current Molecular Medicine Magnesium and Anaesthesia
Current Drug Targets Obstetric Anaesthesia and Obesity
Current Women`s Health Reviews A Stress Repair Mechanism That Maintains Vertebrate Structure During Stress
Cardiovascular & Hematological Disorders-Drug Targets Chemoradiotherapy in Locally Advanced, Unresectable Non-Small Cell Lung Cancer
Reviews on Recent Clinical Trials Melatonin Receptor Agonist Agomelatine: A New Drug for Treating Unipolar Depression
Current Pharmaceutical Design Editorial [ Hot Topic:Addiction and Pain: Cannabinoid and Opioid Interactions (Guest Editor: Sonia Tucci) ]
Current Drug Targets Anti-Inflammatory Effects of Intravenous Anesthetics on Endotoxemia
Mini-Reviews in Medicinal Chemistry Stress Echocardiography
Current Pharmaceutical Design Cardiorenal Consequences of Atherosclerosis and Statins Therapy: From the Past to the Future
Current Pharmaceutical Design Endocannabinoids and Their Receptors: Physiology, Pathology and Pharmacology
Immunology, Endocrine & Metabolic Agents in Medicinal Chemistry (Discontinued) Prevention of Endothelial Cell Injury by Activated Protein C: The Molecular Mechanism(s) and Therapeutic Implications
Current Vascular Pharmacology Management of Hypertension in Relation to Acute Coronary Syndromes and Revascularisation
Current Pharmaceutical Design Amelioration of Myocardial Ischemic Reperfusion Injury with Calendula Officinalis
Current Pharmaceutical Biotechnology Turnover Studies on Cardiac Natriuretic Peptides: Methodological,Pathophysiological and Therapeutical Considerations.
Current Drug Metabolism Editorial(Angiotensin II Receptor Research)
Current Pharmaceutical Design